Bayesian Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-17,400	Closed	-$132K	–	157
2025 Q3	$132K	Buy	+17,400	New	+$145K	0.03%	480
2025 Q1	–	Sell	-25,700	Closed	-$193K	–	621
2024 Q4	$193K	Buy	+25,700	New	+$195K	0.02%	572
2024 Q3	–	Sell	-43,200	Closed	-$267K	–	693
2024 Q2	$267K	Buy	+43,200	New	+$238K	0.03%	535
2024 Q1	–	Sell	-60,600	Closed	-$363K	–	782
2023 Q4	$363K	Sell	60,600 -18,100	-23%	-$105K	0.04%	454
2023 Q3	$557K	Buy	78,700 +63,700	+425%	+$458K	0.06%	350
2023 Q2	$106K	Buy	+15,000	New	+$120K	0.01%	689
2022 Q4	–	Sell	-40,454	Closed	-$510K	–	787
2022 Q3	$510K	Buy	+40,454	New	+$521K	0.1%	277
2020 Q2	–	Sell	-27,100	Closed	-$54K	–	533
2020 Q1	$54K	Buy	+27,100	New	+$74.6K	0.01%	721